RTW INVESTMENTS, LP Acquires Significant Stake in Castle Biosciences Inc.
RTW INVESTMENTS, LP has acquired a substantial stake of 2,115,237 shares in Castle Biosciences Inc. at $38.90 per share, making it 7.20% of their holdings. This strategic investment in the molecular diagnostics company reflects RTW's focus on the healthcare sector and confidence in Castle Biosciences' growth potential. Despite a recent stock price decrease, the company's innovation in medical diagnostics and solid financial strength are highlighted.
Prospective Validation Study in JAAD Demonstrates Castle
A prospective study published in the Journal of the American Academy of Dermatology (JAAD) validated Castle Biosciences' AdvanceAD-Tx™ test for identifying patients with moderate-to-severe atopic dermatitis (AD) who are more likely to respond faster and better to JAK inhibitor therapy. The test stratifies patients by molecular profile, helping clinicians align systemic therapy choices with individual disease biology. Patients with a JAK Inhibitor Responder Profile treated with JAKi showed significantly greater improvements in skin clearance, itch reduction, and quality of life compared to those on Th2-targeted therapies.
New skin test steers severe eczema patients to faster JAK drug relief
Castle Biosciences announced that its AdvanceAD-Tx test can identify patients with moderate-to-severe atopic dermatitis who are more likely to respond significantly better and faster to JAK inhibitor therapy. A prospective study published in JAAD demonstrated that about 30% of patients had a "JAK Inhibitor Responder Profile," achieving EASI-90 nearly four times faster with JAKi treatment compared to Th2-targeted therapies. This molecular insight aims to help clinicians personalize treatment earlier, reducing unnecessary therapy changes and accelerating positive clinical outcomes.
Castle Biosciences Publishes Study Demonstrating AdvanceAD-Tx Test Improves Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis Patients
Castle Biosciences announced the publication of a study validating its AdvanceAD-Tx test, which helps identify moderate-to-severe atopic dermatitis patients who will benefit more from Janus kinase inhibitors. The non-invasive gene expression test identifies a "JAK Inhibitor Responder Profile," leading to significantly better clinical outcomes for these patients compared to those using Th2-targeted therapies. This scientific backing and commercial launch indicate growth potential in personalized dermatological diagnostics, though forward-looking statements note potential risks.
Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
Castle Biosciences announced the publication of a prospective study in JAAD, validating its AdvanceAD-Tx test. The test identifies patients with moderate-to-severe atopic dermatitis more likely to respond significantly better and faster to JAK inhibitor therapy than Th2-targeted therapies. This molecular insight helps clinicians personalize treatment decisions, potentially improving patient outcomes and streamlining care.
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 7% - Should You Sell?
Castle Biosciences (NASDAQ:CSTL) shares dropped 7% on Thursday to $31.32, trading below its 50-day SMA but above its 200-day SMA. Despite recent insider selling and a 54.7% reduction in the COO's position, analysts maintain a "Moderate Buy" consensus with an average price target of $47.14. Institutional investors hold a significant 92.6% of the company's stock.
Castle Biosciences stock jumps after FDA grants Breakthrough Device status to melanoma test
Castle Biosciences (CSTL) shares surged after the FDA granted Breakthrough Device designation to its investigational prognostic test for cutaneous squamous cell carcinoma (cSCC). This designation is expected to accelerate the review process for the test, which aims to identify high-risk cSCC patients. The news led to a significant increase in the company's stock value during intraday trading.
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after the market closes on Thursday, February 26, 2026. Company management will host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss these results. Details for accessing the live webcast and conference call are provided in the announcement.
Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Castle Biosciences (CSTL) shares have recently dropped by 16.8% but may be poised for a trend reversal. Technical indicators like the Relative Strength Index (RSI) show the stock is oversold, while fundamental analysis highlights strong upward revisions in earnings estimates by Wall Street analysts. Additionally, CSTL holds a Zacks Rank #1 (Strong Buy), suggesting a potential near-term turnaround.
Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Castle Biosciences (CSTL) has experienced a 16.8% drop in stock value over the past four weeks, but indicators suggest a potential trend reversal. Its Relative Strength Index (RSI) is at an oversold level of 25.01, and analysts have increased earnings estimates for the current year, leading to a 13.5% rise in the consensus EPS estimate. Furthermore, CSTL holds a Zacks Rank #1 (Strong Buy), pointing towards a near-term turnaround.
Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Castle Biosciences (CSTL) has experienced a 16.8% loss over the past four weeks, but indicators suggest a potential trend reversal. The stock is currently in oversold territory with an RSI of 25.01, and analysts have recently increased their earnings estimates for the company. Furthermore, CSTL holds a Zacks Rank #1 (Strong Buy), pointing to a likely near-term turnaround.
Castle Biosciences, Inc. $CSTL Shares Sold by Allianz Asset Management GmbH
Allianz Asset Management GmbH reduced its stake in Castle Biosciences (NASDAQ:CSTL) by 9.2% in the third quarter, now holding 648,351 shares valued at $14.8 million. Despite this, institutional investors collectively own 92.60% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $47.14. Company insiders have been net sellers, disposing of 39,425 shares worth approximately $1.54 million in the last quarter.
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 3,200 Shares of Stock
Castle Biosciences (NASDAQ:CSTL) insider Derek Maetzold sold 3,200 shares of the company's stock on February 3rd for a total of $127,712, reducing his stake by 3.65%. Following the transaction, Maetzold directly owns 84,515 shares. The stock traded down $2.56 to $32.40 on heavy volume, while institutional investors own 92.6% and analysts maintain a "Moderate Buy" rating with an average price target of $47.14.
Derek Maetzold Sells 817 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
Derek Maetzold, an insider at Castle Biosciences (NASDAQ:CSTL), recently sold 817 shares of the company's stock for approximately $31,038, reducing his total holdings by 0.97%. The sale occurred on February 4th, with shares trading down afterward on heavy volume. Despite the insider selling, Castle Biosciences reported an EPS beat for its last quarter and receives a consensus "Moderate Buy" rating from analysts with an average target price of $47.14.
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Castle Biosciences, Inc. announced it will release its fourth quarter and full-year 2025 financial results after market close on Thursday, Feb. 26, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss these results. Details for accessing the webcast and conference call are provided, including dial-in numbers and a webcast link.
Castle Biosciences to Release Fourth Quarter and Full-Year
Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss these results. Details for accessing the webcast and conference call are provided for investors and interested parties.
Castle Biosciences to Release Fourth Quarter and Full-Year
Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, after market close. The company will also host a conference call and webcast to discuss these results at 4:30 p.m. Eastern time on the same day. Details for accessing the webcast and conference call are provided in the announcement.
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Recommendation of "Moderate Buy" from Analysts
Castle Biosciences (NASDAQ:CSTL) has received an average "Moderate Buy" rating from analysts, with a 12-month average price target of $47.14. Despite recent insider selling totaling $1.67 million, the company reported stronger-than-expected Q3 earnings and revenue. Institutional investors have significantly increased their holdings in CSTL, which specializes in genomic tests for dermatologic conditions.
Are you looking for a top momentum pick? Why Castle Biosciences, Inc. (CSTL) is a great choice
This article identifies Castle Biosciences, Inc. (CSTL) as a strong momentum stock pick. It suggests that CSTL is a favorable choice for investors seeking companies with good recent price performance.
AIGH Capital Management LLC Acquires New Position in Castle Biosciences, Inc. $CSTL
AIGH Capital Management LLC has acquired a new position in Castle Biosciences, Inc. (NASDAQ:CSTL), purchasing 707,287 shares valued at approximately $16.1 million, making it the fund's 9th largest holding. This comes as Castle Biosciences reported strong quarterly earnings, beating analyst estimates for both revenue and EPS. Analysts generally hold a "Moderate Buy" consensus rating with a target price of $46.00 for the company.
Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice
Castle Biosciences, Inc. (CSTL) is highlighted as a strong momentum pick due to its "A" Momentum Style Score and Zacks Rank #1 (Strong Buy). The article details CSTL's positive short-term and long-term price performance, outperforming its industry and the S&P 500, as well as favorable earnings estimate revisions. Investors looking for a stock with strong upward potential are encouraged to consider CSTL.
Castle Biosciences, Inc. (CSTL) Stock Analysis: A Healthcare Innovator with Strong Buy Ratings and 9.13% Upside Potential
Castle Biosciences, Inc. (CSTL) is highlighted as a compelling investment opportunity in the healthcare diagnostics sector, with all analysts rating it a "Buy" and projecting a 9.13% upside potential. The company, which specializes in molecular diagnostic solutions for cancers and mental health, has reached the upper limit of its 52-week range. Despite not yet being profitable, CSTL demonstrates strong operational efficiency with $29.09 million in free cash flow and bullish technical signals, indicating robust investor confidence and a focus on long-term growth through R&D reinvestment.
26,996 Shares in Castle Biosciences, Inc. $CSTL Acquired by Campbell & CO Investment Adviser LLC
Campbell & CO Investment Adviser LLC has acquired a new stake of 26,996 shares in Castle Biosciences (NASDAQ:CSTL), valued at approximately $615,000. Despite this institutional buying, insiders have been net sellers, with the COO significantly reducing her holdings. Analysts maintain a "Moderate Buy" consensus rating for CSTL, with a target price of $46.00, and several firms have raised their price targets to around $50-$52.
Castle Biosciences stock hits 52-week high at $42.25 By Investing.com
Castle Biosciences Inc. (CSTL) reached a 52-week high of $42.25, reflecting a 55.81% increase over the past year and a 151.1% return in the last six months. The company, with a market capitalization of $1.21 billion, has a "GREAT" financial health rating from InvestingPro despite not being profitable in the past year. Recent positive news includes an optimistic 2025 revenue outlook of over $340 million, surpassing previous guidance, and strong performance of its DecisionDx-UM and DecisionDx-Melanoma tests.
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 4,017 Shares
Castle Biosciences (NASDAQ:CSTL) director Derek Maetzold sold 4,017 shares of company stock on January 20th at an average price of $40.01, totaling over $160,000. This sale reduced his stake by 4.38% to 87,715 shares. The company recently reported strong Q3 earnings, beating analyst estimates for EPS and revenue, and analysts currently rate CSTL as a "Moderate Buy" with a consensus price target of $46.
Castle Biosciences stock hits 52-week high at $42.25
Castle Biosciences Inc. (CSTL) reached a 52-week high of $42.25, marking a significant 55.81% increase over the past year and a 151.1% price return in the last six months. The company, despite not being profitable in the last twelve months, has an "GREAT" financial health rating from InvestingPro and is projecting over $340 million in revenue for 2025. This growth is supported by strong performances of its DecisionDx-UM and DecisionDx-Melanoma tests and positive analyst ratings.
Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth
Castle Biosciences (CSTL) recently released upgraded 2025 revenue guidance above US$340 million and showed strong core test volume growth, leading to a 72.47% share price increase over 90 days. Despite this rally, the company is considered modestly undervalued with a narrative fair value of US$42.50, driven by potential improvements in reimbursement and margin structure. However, its Price-to-Sales ratio of 3.3x is higher than the industry average, suggesting the market may be pricing in optimistic assumptions or correcting previous undervaluation.
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Castle Biosciences announced preliminary unaudited results for the fourth quarter and full-year 2025, with total revenue expected to exceed $340 million, surpassing previous guidance. The company saw a 37% increase in total test reports for its core revenue drivers, DecisionDx-Melanoma and TissueCypher, over 2024. Castle Biosciences also highlighted the limited access launch of AdvanceAD-Tx and ended 2025 with approximately $300 million in cash, cash equivalents, and marketable investment securities.
Castle Biosciences (CSTL) Expects 2025 Revenue to Surpass $340 M
Castle Biosciences (CSTL) has projected its 2025 revenue to exceed $340 million, an increase from its earlier guidance, driven by the strong performance of its innovative diagnostic tests. While the company demonstrates robust revenue growth and strong financial health with a high Altman Z-Score, it faces profitability challenges, evidenced by negative EPS and net margin, along with significant insider selling activity. Investors are advised to monitor sector-specific risks and upcoming catalysts.
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Castle Biosciences announced strong preliminary unaudited results for Q4 and full-year 2025, with total revenue expected to exceed $340 million, surpassing previous guidance. The company reported a significant increase in test reports for its core revenue drivers, DecisionDx-Melanoma and TissueCypher, and successfully launched its new AdvanceAD-Tx test. Castle Biosciences attributes this performance to its innovative test portfolio and solidifies its financial position with approximately $300 million in cash, cash equivalents, and marketable investment securities at year-end.
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Castle Biosciences (Nasdaq: CSTL) announced preliminary unaudited results for Q4 and full-year 2025, with total revenue expected to exceed $340 million, surpassing previous guidance. The company reported a 37% increase in total test reports for its core revenue drivers, DecisionDx-Melanoma and TissueCypher, over 2024. Castle Biosciences also highlighted the limited access launch of AdvanceAD-Tx and a strong year-end cash position of approximately $300 million.
Castle Biosciences Expects 2025 Revenue to Exceed $340 Million
Castle Biosciences projects its 2025 revenue to surpass $340 million, an increase from its earlier guidance, driven by a 37% rise in core test reports for DecisionDx-Melanoma and TissueCypher. The successful launch of AdvanceAD-Tx also contributed to this optimistic outlook. The company maintains a strong financial position with approximately $300 million in cash and $184 million in marketable securities by the end of 2025, supporting future expansion.
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts
Castle Biosciences, Inc. (NASDAQ:CSTL) has received a consensus "Moderate Buy" rating from eight analysts, with an average 12-month price target of approximately $43.17. Despite recent insider selling, including a significant reduction by the COO, insiders still own 7.2% and institutions own 92.6% of the stock. The company recently beat quarterly estimates, reporting EPS of ($0.02) against an estimated ($0.34) and revenue of $80.6 million against an estimated $71.1 million.
Castle Biosciences, Inc. (CSTL) Stock Analysis: Riding the Wave of Healthcare Innovation with 9.68% Upside Potential
Castle Biosciences, Inc. (CSTL) is a healthcare company focused on molecular diagnostics for dermatologic cancers and mental health conditions. While not currently profitable, the company shows strong growth potential, evidenced by its significant stock appreciation and bullish analyst ratings predicting a 9.68% upside. Its portfolio of gene expression profile tests positions it to capitalize on the increasing demand for personalized medicine.
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 1,339 Shares of Stock
Castle Biosciences insider Derek Maetzold sold 1,339 shares of the company's stock on January 6th, reducing his stake by 4.34%. The shares were sold at an average price of $40.10, totaling $53,693.90. Despite this insider sale, analysts maintain a "Moderate Buy" rating for CSTL with a consensus price target of $43.17.
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 830 Shares
Castle Biosciences (NASDAQ:CSTL) insider Derek Maetzold sold 830 shares of the company's stock for $33,490.50 on December 22nd, reducing his stake by 2.42%. The sale comes as the company's stock trades near its 1-year high, with recent positive earnings surprises and several analysts raising price targets on CSTL. The company has a "Moderate Buy" consensus rating among analysts with an average target price of $41.00.
Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus
This article highlights how Zacks' investment strategies have helped various stocks outperform the market. It discusses the success of Zacks Rank upgrades for Castle Biosciences and F.N.B. Corporation, as well as the strong performance of stocks from Zacks Recommendation, Focus List, ECAP, and ECDP, including Hamilton Insurance, Huntington Ingalls, Monster Beverage, Johnson & Johnson, and MasTec. The report emphasizes Zacks' methodologies in identifying winning stocks across different market conditions.
Castle Biosciences stock hits 52-week high at 40.66 USD
Castle Biosciences Inc. (CSTL) recently hit a new 52-week high of $40.74, reflecting a strong upward trend with a 43.26% increase over the past year and a 112.96% surge in the last six months. This growth is supported by solid financial health and investor confidence, despite the company not yet being profitable, with analysts maintaining a "Strong Buy" consensus and a $50 price target. Recent positive developments include exceeding Q3 2025 revenue estimates, improved EPS, and advancements in diagnostic tests, leading to raised price targets from BTIG and Canaccord Genuity.
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group has increased its price target for Castle Biosciences (NASDAQ:CSTL) to $50.00 from $37.00, maintaining a "buy" rating and indicating a potential upside of 26.77%. This upgrade follows Castle Biosciences' recent earnings beat, where the company reported an EPS of ($0.02) and revenue of $80.55 million, both exceeding analyst expectations. The stock currently holds a "Moderate Buy" consensus rating among analysts with an average target price of $41.00.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences, Inc. announced the granting of restricted stock units (RSUs) to 83 employees, covering an aggregate of 139,494 shares of common stock. These grants were made on December 15, 2025, as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting on the first anniversary and the remainder annually thereafter.
Castle Biosciences (NASDAQ:CSTL) Insider Sells $20,380.36 in Stock
Derek Maetzold, an insider at Castle Biosciences (NASDAQ:CSTL), sold 509 shares for $20,380.36 on December 17, reducing his position by 1.46%. The company's stock is currently trading near its 52-week high, with a market capitalization of $1.15 billion and a negative P/E of -87.6. Institutions own approximately 92.6% of the stock, and analysts have a consensus "Moderate Buy" rating with a $39.14 price target.
Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 14,888 Shares
Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager sold 14,888 shares of the company's stock, reducing her ownership by over 54%. The transaction, valued at approximately $585,247, occurred on December 17th. Despite the insider sale, Castle Biosciences recently reported strong quarterly results, beating analyst expectations for both EPS and revenue, while maintaining a "Moderate Buy" consensus rating from analysts.
Castle Biosciences (CSTL) Awards Restricted Stock Units to New Employees
Castle Biosciences (CSTL) has awarded restricted stock units (RSUs) to 83 new employees, totaling 139,494 shares, as part of an incentive strategy to recruit talent. The RSUs vest over four years, with 25% vesting after the first year and the remainder annually. Despite profitability challenges and insider selling, Castle Biosciences exhibits strong financial health and a robust balance sheet, positioning it as a significant player in the medical diagnostics and research industry.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences, Inc. (Nasdaq: CSTL) announced inducement grants of restricted stock units (RSUs) to 83 employees totaling 139,494 shares of common stock. These grants were made on December 15, 2025, under the Company’s 2022 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting on the first anniversary and the remainder in three equal annual installments, subject to continued employment.
Squarepoint Ops LLC Buys 28,359 Shares of Castle Biosciences, Inc. $CSTL
Squarepoint Ops LLC increased its stake in Castle Biosciences (NASDAQ:CSTL) by 29.1% during the second quarter, now owning 125,719 shares valued at $2.57 million. Despite institutional buying, company insiders have been net sellers, with total insider sales reaching $1.06 million in the last 90 days. Analysts maintain a "Moderate Buy" rating for Castle Biosciences with a consensus target price of $39.14, while the company trades near its 52-week high with a market cap of $1.16 billion.
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
A landmark study published in Nature Communications by the Collaborative Ocular Oncology Group (COOG) found that combining Castle Biosciences' DecisionDx-UM test results and PRAME gene expression data provides superior prediction of metastasis-free and overall survival in uveal melanoma patients compared to gene mutation analysis. DecisionDx-UM + PRAME offers a more comprehensive view of the tumor microenvironment, leading to more accurate risk stratification. This combined approach assists in guiding informed treatment decisions for patients with this aggressive eye cancer.
Castle Biosciences Announces Key Study Findings on Uveal Melanoma Risk Stratification Using DecisionDx-UM and PRAME Combination
Castle Biosciences announced findings from a multicenter study published in Nature Communications, demonstrating that combining their DecisionDx-UM and PRAME gene expression tests significantly improves predictions for metastasis-free and overall survival in uveal melanoma patients compared to next-generation sequencing (NGS) alone. The study analyzed over 1,140 tumors, highlighting the superior predictive capability of the combined approach due to its assessment of gene activity from both tumor and surrounding immune cells. This validation reinforces the adoption of these tests for better patient management in this aggressive cancer.
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
A new study published in Nature Communications demonstrates that the combination of Castle Biosciences' DecisionDx-UM and PRAME tests provides superior predictions of metastasis-free and overall survival in uveal melanoma patients compared to next-generation sequencing-based gene mutation analysis. This research, conducted by the Collaborative Ocular Oncology Group (COOG), highlights that integrating gene expression data offers a more comprehensive view of tumor biology, leading to enhanced risk stratification and more informed treatment decisions for this aggressive eye cancer. Castle Biosciences offers these tests to provide comprehensive molecular insights for UM patients.
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Rating of "Moderate Buy" from Analysts
Castle Biosciences, Inc. (NASDAQ:CSTL) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of $39.14. The company recently reported a quarterly EPS beat and higher-than-expected revenue. Despite strong liquidity, there has been recent insider selling of approximately 35,876 shares.
BTIG Maintains Castle Biosciences (CSTL) Buy Recommendation
BTIG maintained its Buy recommendation for Castle Biosciences (CSTL) on December 12, 2025. Analysts project a 1.41% upside with an average one-year price target of $38.50/share. Institutional ownership shows slight shifts, with Principal Financial Group, Portolan Capital Management, and Nuveen as significant holders.
